Stay updated on Bemcentinib-Pembrolizumab Combo in Advanced NSCLC Clinical Trial
Sign up to get notified when there's something new on the Bemcentinib-Pembrolizumab Combo in Advanced NSCLC Clinical Trial page.

Latest updates to the Bemcentinib-Pembrolizumab Combo in Advanced NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe record presents details of the completed Phase 2 study of bemcentinib plus pembrolizumab for advanced lung cancer, including study outcomes, eligibility, participating locations, and supporting documents.SummaryDifference69%

- Check19 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide banner announces an NIH terminology transition, saying “Super Intelligence” is being used in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check33 days agoChange DetectedThe footer's site revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check40 days agoChange DetectedThe page remains a 403 Forbidden error page, while the footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check61 days agoChange DetectedThe study page now shows a 403 Forbidden error with a minimal header and a Home link, replacing the previous detailed study content and sections.SummaryDifference21%

Stay in the know with updates to Bemcentinib-Pembrolizumab Combo in Advanced NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bemcentinib-Pembrolizumab Combo in Advanced NSCLC Clinical Trial page.